LAGUNA
BEACH, Calif., July 17,
2024 /PRNewswire/ -- Ryght, a leading enterprise
generative AI (GenAI) technology company dedicated to improving
clinical research, proudly announces its new partnership with
CancerX, a public-private partnership aimed at boosting innovation
in the fight against cancer.
CancerX, launched in February 2023
as part of the White House's reinvigorated Cancer Moonshot, is a
public-private partnership co-hosted by the Moffitt Cancer Center
and the Digital Medicine Society (DiMe), alongside the Office for
the National Coordinator for Health Information Technology (ONC)
and the Office of the Assistant Secretary for Health (OASH). As a
CancerX member, Ryght joins other leaders in oncology and digital
health to set priorities and practices aimed at harnessing the full
power of innovation to combat cancer.
"We are thrilled to join forces with CancerX and contribute to
this monumental effort," said Chadi
Nabhan, MD, MBA, Chief Medical Officer and Head of Strategy
at Ryght. "Our mission at Ryght is to empower the clinical trials
industry with cutting-edge AI solutions that enhance research and
operations to improve clinical outcomes. By collaborating with
CancerX, we can accelerate the adoption of AI-driven innovations
that drive clinical research and make a positive impact on the way
cancer care is delivered for all patients everywhere."
Ryght is a secure, world-class generative AI software
platform featuring industry-leading copilots and applications
designed for clinical research sites and trial sponsors. These
copilots help sites, sponsors, and CROs operate more efficiently,
increase revenue, reduce costs, and uncover new opportunities.
Ryght's vision is to create a global network of AI-enabled
partners, utilizing AI as the underlying fabric to connect systems
and enhance collaboration.
CancerX establishes best practices, builds capacity, and
demonstrates the impact of innovation on the life of every person
on a cancer journey. By integrating Ryght's advanced GenAI
solutions into this work, CancerX aims to further enhance these
initiatives, ultimately improving the quality of life for cancer
patients and their families.
"CancerX is the home for collaborators to harness the collective
power of digital innovation in the fight against cancer, and we're
honored to welcome Ryght to work with us as we achieve the
ambitious goals of the Cancer Moonshot," said Doug Mirsky, Vice President, DiMe. "Together we
are establishing best practices, building capacity, and
demonstrating the impact of digital innovation to improve the lives
of every person on a cancer journey."
About CancerX
Announced by the White House Cancer
Moonshot in February, CancerX is a public-private partnership to
boost innovation in the fight against cancer. Co-hosted by the
Moffitt Cancer Center and Digital Medicine Society (DiMe),
alongside the Office for the National Coordinator for Health
Information Technology (ONC) and Office of the Assistant Secretary
for Health (OASH), it convenes the many diverse stakeholders needed
to unleash the power of innovation to reduce the burden of cancer
for everyone. To learn more or participate in CancerX's
pre-competitive, evidence-generating efforts, Accelerator cohort,
or demonstration projects, sign up today.
About Ryght
Ryght is a privately held healthcare technology company based in
California, USA, that is
developing the next generation of safe and secure generative
artificial intelligence (GenAI) solutions for the clinical research
industry. The Ryght platform securely leverages and optimizes
multiple industry specific copilots and AI applications across
multiple large language models (LLMs) with its unique orchestration
platform that ingests real-time data streams and makes actionable
knowledge directly available to biopharma discovery, clinical, and
commercial teams. The platform enables healthcare professionals to
rapidly leverage the power of GenAI within compliance of data
security standards required by the industry. To learn more about
Ryght's generative AI solutions or discuss collaboration
opportunities, please email sales@ryght.ai or contact us.
Contact:
Ryght PR Team
Email: hello@ryght.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ryght-joins-prestigious-cancerx-program-to-accelerate-innovation-in-cancer-research-302198848.html
SOURCE Ryght